Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil

Journal of Viral Hepatitis

Volumn 20, Issue SUPPL.1, 2013, Pages 40-45

  Lu, Jia Jie ^a,b   Liu, Kai ^a,b   Ma, Yuan Ji ^a,b   Wang, Juan ^a,b   Chen, En Qiang ^a,b   Tang, Hong ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

adefovir resistance; chronic hepatitis B; combination therapy; telbivudine plus adefovir

Indexed keywords

ADEFOVIR DIPIVOXIL; ENTECAVIR; HEPATITIS B(E) ANTIGEN; TELBIVUDINE; VIRUS DNA;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; SEROCONVERSION; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

ADENINE; ADULT; ANTIVIRAL AGENTS; CHINA; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; ORGANOPHOSPHONATES; PROSPECTIVE STUDIES; THYMIDINE; TREATMENT OUTCOME;

EID: 84874623068     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12062     Document Type: Article

References (37)

1. Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV,. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004; 38 (10 Suppl. 3): S158-168.
2. Yim HJ, Lok AS,. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and we know in 2005. Hepatology 2006; 43 (2 Suppl. 1): S173-181.
3. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
4. Liu S, Zhang H, Gu C, et al,. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst 2009; 101: 1066-1082.
5. Zhang QQ, An X, Liu YH, et al,. Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the Risk of long-term complications: a meta-analysis. Virol J 2011; 8: 72.
6. Yang YF, Zhao W, Zhong YD, Xia HM, Shen L, Zhang N,. Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat 2009; 16 (4): 265-271.
7. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
8. Keeffe EB, Dieterich DT, Han SH, et al,. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6 (12): 1315-1341.
9. Liaw YF, Leung N, Kao JH, et al,. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2 (3): 263-283.
10. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al,. Adefovir Dipivoxil 438 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-807. (Pubitemid 36245756)
11. Marcellin P, Chang TT, Lim SG, et al,. Adefovir dipivoxil 437 study group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-816. (Pubitemid 36245757)
12. Perrillo R, Schiff E, Yoshida E, et al,. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32 (1): 129-134. (Pubitemid 30432377)
13. Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS,. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998; 28: 1669-1673. (Pubitemid 28549139)
14. Marcellin P, Chang TT, Lim SG, et al,. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008; 48 (3): 750-758.
15. Ghany MG, Doo EC,. Antiviral resistance and hepatitis B therapy. Hepatology 2009; 49 (5 Suppl): S174-184.
16. Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WE IV,. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005; 10: 625-633. (Pubitemid 41224954)
17. Brunelle MN, Jacquard AC, Pichoud C, et al,. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005; 41: 1391-1398. (Pubitemid 40770292)
18. Van Bommel F, Zollner B, Sarrazin C, et al,. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006; 44: 318-325. (Pubitemid 44214870)
19. Angus P, Vaughan R, Xiong S, et al,. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292-297. (Pubitemid 36929407)
20. Villeneuve JP, Durantel D, Durantel S, et al,. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003; 39: 1085-1089. (Pubitemid 37523785)
21. Lok AS, Lai CL, Leung N, et al,. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-1722. (Pubitemid 37500436)
22. Yao GB, Wang BE, Cui ZY, Yao JL, Zeng MD,. The long-term efficacy of lamivudine in chronic hepatitis B: interim analysis of 3 year's clinical course. Chin J Intern Med (Chin) 2003a; 42: 382-387.
23. Yao GB, Cui ZY, Yao JL, Zhang DF, Ji NX, Huang Y,. Chronic hepatitis B treated with domestic manufactured lamivudine in 2200 patients: a phase IV study. Chin J Hepatol (Chin) 2003b; 11: 103-108.
24. Villet S, Pichoud C, Billioud G, et al,. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008; 48: 747-755.
25. Liaw YF, Gane E, Leung N, et al,. GLOBE Study Group. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136 (2): 486-495.
26. Chang TT, Gish RG, de Man R, et al,. BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-1010. (Pubitemid 43357804)
27. Tenney DJ, Pokornoski KA, Rose RE, et al,. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance. Hepatol Int 2008; 2: A88-A89.
28. Liaw YF,. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir Ther 2006; 11 (6): 669-679.
29. Sheng YJ, Liu JY, Tong SW, et al,. Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. Virol J 2011; 8: 393.
30. Lai CL, Shouval D, Lok AS, et al,. BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-1020. (Pubitemid 43357805)
31. Chan HL, Heathcote EJ, Marcellin P, et al,. 018 Study Group. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007; 147 (11): 745-754. (Pubitemid 351664439)
32. Leung N, Peng CY, Sollano J, et al,. for the Entecavir Viral Kinetics Group. Entecavir (ETV) results in higher HBV-DNA reduction vs adefovir (ADV) in chronically infected HBeAg(+) antiviral-naive adults: 48-wk results (EARLY study). J Hepatol 2007; 46 (Suppl. 1): S23. Abstract.
33. Chen CJ, Yang HI, Su J, et al,. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295 (1): 65-73. (Pubitemid 43042691)
34. lloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ,. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130 (3): 678-686. (Pubitemid 43374518)
35. Chen EQ, Wang LC, Lei J, Xu L, Tang H,. Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus. Virol J 2009; 6: 163.
36. Hartwell D, Jones J, Harris P, Cooper K,. Telbivudine for the treatment of chronic hepatitis B infection. Health Technol Assess 2009; 13 (Suppl. 3): 23-30.
37. McKeage K, Keam SJ,. Telbivudine: a review of its use in compensated chronic hepatitis B. Drugs 2010; 70 (14): 1857-1883.